Assessment of Serum Pepsinogens with and without Co-Testing with Gastrin-17 in Gastric Cancer Risk Assessment—Results from the GISTAR Pilot Study

Assessment of Serum Pepsinogens with and without Co-Testing with Gastrin-17 in Gastric Cancer Risk Assessment—Results from the GISTAR Pilot Study

Introduction––Serum pepsinogen tests for gastric cancer screening have been debated for decades. We assessed the performance of two pepsinogen assays with or without gastrin-17 for the detection of different precancerous lesions alone or as a composite endpoint in a Latvian cohort. Methods––Within t...

Full description

Bibliographic Details
Main Authors: Claudia Robles, Dace Rudzite, Inese Polaka, Olga Sjomina, Lilian Tzivian, Ilze Kikuste, Ivars Tolmanis, Aigars Vanags, Sergejs Isajevs, Inta Liepniece-Karele, Danute Razuka-Ebela, Sergej Parshutin, Raul Murillo, Rolando Herrero, Jin Young Park, Marcis Leja
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Diagnostics
Subjects:
serum pepsinogens
gastrin-17
gastric cancer prevention
screening
public health
Online Access:https://www.mdpi.com/2075-4418/12/7/1746

Internet

https://www.mdpi.com/2075-4418/12/7/1746

Similar Items